Use of Hsp90 Protein Inhibiting Compounds and Pharmaceutical Composition Intended for Anti-tumour Therapy
The invention relates to a method for designing an individual anti-tumour therapy for a patient based on the detection of the levels of the Hsp90 protein responsible for resistance to a drug or a mixture of anti-tumour drugs that inhibit receptors IGF1R/KIT. The invention also relates to the use of Hsp90 protein inhibitors for the production of drugs for the treatment of tumours resistant to IGF1R/KIT inhibitors, the resulting pharmaceutical compositions and the use thereof on Ewing's sarcoma tumours.
Patents:WO 2,009,138,542
Inventor(s):
DE ALAVA CASADO ENRIQUE [ES]; DA SILVA MARTINS ANA SOFIA [ES]
Type of Offer:
Sale
« More Pharmaceutical Patents